Drug Approval | April 10, 2024
Shivalik Rasayan’s API facility gets 7 observations from USFDA
These observations are procedural in nature and will be responded within the stipulated time
These observations are procedural in nature and will be responded within the stipulated time
The observations are procedural in nature and will be responded to within the stipulated time
Highly effective preservation solutions ensuring the safety and protection of personal care products
WINREVAIR is a breakthrough biologic for this rare, progressive disease
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Subscribe To Our Newsletter & Stay Updated
